Leonardo Venturelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Leonardo Venturelli has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Andrea Pession
7 shared publicationsAnna Lisa Scardovi
7 shared publicationsCamilla Amadesi
7 shared publicationsDamiano Bartolucci
7 shared publicationsGabriella Teti
7 shared publicationsGiammario Nieddu
7 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods and Fig s1-s13 from A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma
Figure S1: BGA002 induces apoptosis Figure S2: BGA002 inhibits MYCN expression in a broad neuroblastoma cell-line panel Figure S3: BGA002 is a specific MYCN inhibitor Figure S4: Mitochondria structural alteration are MYCN specific inhibition. Figure S5: BGA002 leads to MYCN-specific structural alteration in mitochondria. Figure S6: BGA001 does not lead to significant MYCN-specific structural alteration in mitochondria. Figure S7: MYCN inhibition leads to mitochondrial damage Figure S8: Alterations in mitochondrial pathways identify Neuroblastoma patients with poor prognosis. Figure S9: MYCN amplified patient are enriched for the mitochondrial gene signature. Figure S10: MYCN blocking leads to MYCN specific gene expression signature inhibition in NB cells and to mitophagy reactivation. Figure S11: OPTN controls mitophagy induction after MYCN silencing Figure S12: BGA002 reverts the MYCN control of ROS generation by TRAP1 down-regulation in MNA-NB cells. Figure S13: BGA002 causes elimination of MYCN-NB in mice
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods and Fig s1-s13 from A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma
Figure S1: BGA002 induces apoptosis Figure S2: BGA002 inhibits MYCN expression in a broad neuroblastoma cell-line panel Figure S3: BGA002 is a specific MYCN inhibitor Figure S4: Mitochondria structural alteration are MYCN specific inhibition. Figure S5: BGA002 leads to MYCN-specific structural alteration in mitochondria. Figure S6: BGA001 does not lead to significant MYCN-specific structural alteration in mitochondria. Figure S7: MYCN inhibition leads to mitochondrial damage Figure S8: Alterations in mitochondrial pathways identify Neuroblastoma patients with poor prognosis. Figure S9: MYCN amplified patient are enriched for the mitochondrial gene signature. Figure S10: MYCN blocking leads to MYCN specific gene expression signature inhibition in NB cells and to mitophagy reactivation. Figure S11: OPTN controls mitophagy induction after MYCN silencing Figure S12: BGA002 reverts the MYCN control of ROS generation by TRAP1 down-regulation in MNA-NB cells. Figure S13: BGA002 causes elimination of MYCN-NB in mice
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma
Approximately half of high-risk neuroblastoma is characterized by MYCN amplification. N-Myc promotes tumor progression by inducing cell growth and inhibiting differentiation. MYCN has also been shown to play an active role in mitochondrial metabolism, but this relationship is not well understood. Although N-Myc is a known driver of the disease, it remains a target for which no therapeutic drug exists. Here, we evaluated a novel MYCN-specific antigene PNA oligonucleotide (BGA002) in MYCN-amplified (MNA) or MYCN-expressing neuroblastoma and investigated the mechanism of its antitumor activity. MYCN mRNA and cell viability were reduced in a broad set of neuroblastoma cell lines following BGA002 treatment. Furthermore, BGA002 decreased N-Myc protein levels and apoptosis in MNA neuroblastoma. Analysis of gene expression data from patients with neuroblastoma revealed that MYCN was associated with increased reactive oxygen species (ROS), downregulated mitophagy, and poor prognosis. Inhibition of MYCN caused profound mitochondrial damage in MNA neuroblastoma cells through downregulation of the mitochondrial molecular chaperone TRAP1, which subsequently increased ROS. Correspondingly, inhibition of MYCN reactivated mitophagy. Systemic administration of BGA002 downregulated N-Myc and TRAP1, with a concomitant decrease in MNA neuroblastoma xenograft tumor weight. In conclusion, this study highlights the role of N-Myc in blocking mitophagy in neuroblastoma and in conferring protection to ROS in mitochondria through upregulation of TRAP1. BGA002 is a potently improved MYCN-specific antigene oligonucleotide that reverts N-Myc–dysregulated mitochondrial pathways, leading to loss of the protective effect of N-Myc against mitochondrial ROS.Significance:A second generation antigene peptide oligonucleotide targeting MYCN induces mitochondrial damage and inhibits growth of MYCN-amplified neuroblastoma cells.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma
Approximately half of high-risk neuroblastoma is characterized by MYCN amplification. N-Myc promotes tumor progression by inducing cell growth and inhibiting differentiation. MYCN has also been shown to play an active role in mitochondrial metabolism, but this relationship is not well understood. Although N-Myc is a known driver of the disease, it remains a target for which no therapeutic drug exists. Here, we evaluated a novel MYCN-specific antigene PNA oligonucleotide (BGA002) in MYCN-amplified (MNA) or MYCN-expressing neuroblastoma and investigated the mechanism of its antitumor activity. MYCN mRNA and cell viability were reduced in a broad set of neuroblastoma cell lines following BGA002 treatment. Furthermore, BGA002 decreased N-Myc protein levels and apoptosis in MNA neuroblastoma. Analysis of gene expression data from patients with neuroblastoma revealed that MYCN was associated with increased reactive oxygen species (ROS), downregulated mitophagy, and poor prognosis. Inhibition of MYCN caused profound mitochondrial damage in MNA neuroblastoma cells through downregulation of the mitochondrial molecular chaperone TRAP1, which subsequently increased ROS. Correspondingly, inhibition of MYCN reactivated mitophagy. Systemic administration of BGA002 downregulated N-Myc and TRAP1, with a concomitant decrease in MNA neuroblastoma xenograft tumor weight. In conclusion, this study highlights the role of N-Myc in blocking mitophagy in neuroblastoma and in conferring protection to ROS in mitochondria through upregulation of TRAP1. BGA002 is a potently improved MYCN-specific antigene oligonucleotide that reverts N-Myc–dysregulated mitochondrial pathways, leading to loss of the protective effect of N-Myc against mitochondrial ROS.Significance:A second generation antigene peptide oligonucleotide targeting MYCN induces mitochondrial damage and inhibits growth of MYCN-amplified neuroblastoma cells.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods and Fig s1-s13 from A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma
Figure S1: BGA002 induces apoptosis Figure S2: BGA002 inhibits MYCN expression in a broad neuroblastoma cell-line panel Figure S3: BGA002 is a specific MYCN inhibitor Figure S4: Mitochondria structural alteration are MYCN specific inhibition. Figure S5: BGA002 leads to MYCN-specific structural alteration in mitochondria. Figure S6: BGA001 does not lead to significant MYCN-specific structural alteration in mitochondria. Figure S7: MYCN inhibition leads to mitochondrial damage Figure S8: Alterations in mitochondrial pathways identify Neuroblastoma patients with poor prognosis. Figure S9: MYCN amplified patient are enriched for the mitochondrial gene signature. Figure S10: MYCN blocking leads to MYCN specific gene expression signature inhibition in NB cells and to mitophagy reactivation. Figure S11: OPTN controls mitophagy induction after MYCN silencing Figure S12: BGA002 reverts the MYCN control of ROS generation by TRAP1 down-regulation in MNA-NB cells. Figure S13: BGA002 causes elimination of MYCN-NB in mice
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods and Fig s1-s13 from A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma
Figure S1: BGA002 induces apoptosis Figure S2: BGA002 inhibits MYCN expression in a broad neuroblastoma cell-line panel Figure S3: BGA002 is a specific MYCN inhibitor Figure S4: Mitochondria structural alteration are MYCN specific inhibition. Figure S5: BGA002 leads to MYCN-specific structural alteration in mitochondria. Figure S6: BGA001 does not lead to significant MYCN-specific structural alteration in mitochondria. Figure S7: MYCN inhibition leads to mitochondrial damage Figure S8: Alterations in mitochondrial pathways identify Neuroblastoma patients with poor prognosis. Figure S9: MYCN amplified patient are enriched for the mitochondrial gene signature. Figure S10: MYCN blocking leads to MYCN specific gene expression signature inhibition in NB cells and to mitophagy reactivation. Figure S11: OPTN controls mitophagy induction after MYCN silencing Figure S12: BGA002 reverts the MYCN control of ROS generation by TRAP1 down-regulation in MNA-NB cells. Figure S13: BGA002 causes elimination of MYCN-NB in mice
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma
Approximately half of high-risk neuroblastoma is characterized by MYCN amplification. N-Myc promotes tumor progression by inducing cell growth and inhibiting differentiation. MYCN has also been shown to play an active role in mitochondrial metabolism, but this relationship is not well understood. Although N-Myc is a known driver of the disease, it remains a target for which no therapeutic drug exists. Here, we evaluated a novel MYCN-specific antigene PNA oligonucleotide (BGA002) in MYCN-amplified (MNA) or MYCN-expressing neuroblastoma and investigated the mechanism of its antitumor activity. MYCN mRNA and cell viability were reduced in a broad set of neuroblastoma cell lines following BGA002 treatment. Furthermore, BGA002 decreased N-Myc protein levels and apoptosis in MNA neuroblastoma. Analysis of gene expression data from patients with neuroblastoma revealed that MYCN was associated with increased reactive oxygen species (ROS), downregulated mitophagy, and poor prognosis. Inhibition of MYCN caused profound mitochondrial damage in MNA neuroblastoma cells through downregulation of the mitochondrial molecular chaperone TRAP1, which subsequently increased ROS. Correspondingly, inhibition of MYCN reactivated mitophagy. Systemic administration of BGA002 downregulated N-Myc and TRAP1, with a concomitant decrease in MNA neuroblastoma xenograft tumor weight. In conclusion, this study highlights the role of N-Myc in blocking mitophagy in neuroblastoma and in conferring protection to ROS in mitochondria through upregulation of TRAP1. BGA002 is a potently improved MYCN-specific antigene oligonucleotide that reverts N-Myc–dysregulated mitochondrial pathways, leading to loss of the protective effect of N-Myc against mitochondrial ROS.Significance:A second generation antigene peptide oligonucleotide targeting MYCN induces mitochondrial damage and inhibits growth of MYCN-amplified neuroblastoma cells.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma
Approximately half of high-risk neuroblastoma is characterized by MYCN amplification. N-Myc promotes tumor progression by inducing cell growth and inhibiting differentiation. MYCN has also been shown to play an active role in mitochondrial metabolism, but this relationship is not well understood. Although N-Myc is a known driver of the disease, it remains a target for which no therapeutic drug exists. Here, we evaluated a novel MYCN-specific antigene PNA oligonucleotide (BGA002) in MYCN-amplified (MNA) or MYCN-expressing neuroblastoma and investigated the mechanism of its antitumor activity. MYCN mRNA and cell viability were reduced in a broad set of neuroblastoma cell lines following BGA002 treatment. Furthermore, BGA002 decreased N-Myc protein levels and apoptosis in MNA neuroblastoma. Analysis of gene expression data from patients with neuroblastoma revealed that MYCN was associated with increased reactive oxygen species (ROS), downregulated mitophagy, and poor prognosis. Inhibition of MYCN caused profound mitochondrial damage in MNA neuroblastoma cells through downregulation of the mitochondrial molecular chaperone TRAP1, which subsequently increased ROS. Correspondingly, inhibition of MYCN reactivated mitophagy. Systemic administration of BGA002 downregulated N-Myc and TRAP1, with a concomitant decrease in MNA neuroblastoma xenograft tumor weight. In conclusion, this study highlights the role of N-Myc in blocking mitophagy in neuroblastoma and in conferring protection to ROS in mitochondria through upregulation of TRAP1. BGA002 is a potently improved MYCN-specific antigene oligonucleotide that reverts N-Myc–dysregulated mitochondrial pathways, leading to loss of the protective effect of N-Myc against mitochondrial ROS.Significance:A second generation antigene peptide oligonucleotide targeting MYCN induces mitochondrial damage and inhibits growth of MYCN-amplified neuroblastoma cells.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary tables from A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma
Supplementary tables Supplementary Table 1: List of cell lines used in this study. Supplementary Table 2: List of the primers used in this study for quantitative Real Time PCR. Supplementary Table 3: Table showing the EC50 effect for BGA001 and BGA002 (MYCN mRNA, decrease in cell viability, N-myc protein and apoptosis induction in Kelly and SK-N-BE(2)c cell lines). Supplementary Table 4: List of genes present in the Mitochondrial-related signature in alphabetical order. Supplementary Table 5: Table summarizing principal patient features and their cluster attribution. More extensive information can be seen at http://www.ebi.ac.uk/arrayexpress; accession: E-MTAB-1781. Supplementary Table 6: Table summarizing the mitoscore and its components for each gene of the mitochondrial signature; genes are order based on decreasing mitoscore. Supplementary Table 7: List of the top 200 differentially expressed genes between Cluster 1 (left) and Cluster 2 (right) Supplementary Table 8: List of Cluster 1 and Cluster 2 associated genes used for the pathway network analysis. Supplementary Table 9: List of the ClueGo pathways obtained from the pathway network analysis.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary tables from A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma
Supplementary tables Supplementary Table 1: List of cell lines used in this study. Supplementary Table 2: List of the primers used in this study for quantitative Real Time PCR. Supplementary Table 3: Table showing the EC50 effect for BGA001 and BGA002 (MYCN mRNA, decrease in cell viability, N-myc protein and apoptosis induction in Kelly and SK-N-BE(2)c cell lines). Supplementary Table 4: List of genes present in the Mitochondrial-related signature in alphabetical order. Supplementary Table 5: Table summarizing principal patient features and their cluster attribution. More extensive information can be seen at http://www.ebi.ac.uk/arrayexpress; accession: E-MTAB-1781. Supplementary Table 6: Table summarizing the mitoscore and its components for each gene of the mitochondrial signature; genes are order based on decreasing mitoscore. Supplementary Table 7: List of the top 200 differentially expressed genes between Cluster 1 (left) and Cluster 2 (right) Supplementary Table 8: List of Cluster 1 and Cluster 2 associated genes used for the pathway network analysis. Supplementary Table 9: List of the ClueGo pathways obtained from the pathway network analysis.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary tables from A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma
Supplementary tables Supplementary Table 1: List of cell lines used in this study. Supplementary Table 2: List of the primers used in this study for quantitative Real Time PCR. Supplementary Table 3: Table showing the EC50 effect for BGA001 and BGA002 (MYCN mRNA, decrease in cell viability, N-myc protein and apoptosis induction in Kelly and SK-N-BE(2)c cell lines). Supplementary Table 4: List of genes present in the Mitochondrial-related signature in alphabetical order. Supplementary Table 5: Table summarizing principal patient features and their cluster attribution. More extensive information can be seen at http://www.ebi.ac.uk/arrayexpress; accession: E-MTAB-1781. Supplementary Table 6: Table summarizing the mitoscore and its components for each gene of the mitochondrial signature; genes are order based on decreasing mitoscore. Supplementary Table 7: List of the top 200 differentially expressed genes between Cluster 1 (left) and Cluster 2 (right) Supplementary Table 8: List of Cluster 1 and Cluster 2 associated genes used for the pathway network analysis. Supplementary Table 9: List of the ClueGo pathways obtained from the pathway network analysis.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary tables from A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma
Supplementary tables Supplementary Table 1: List of cell lines used in this study. Supplementary Table 2: List of the primers used in this study for quantitative Real Time PCR. Supplementary Table 3: Table showing the EC50 effect for BGA001 and BGA002 (MYCN mRNA, decrease in cell viability, N-myc protein and apoptosis induction in Kelly and SK-N-BE(2)c cell lines). Supplementary Table 4: List of genes present in the Mitochondrial-related signature in alphabetical order. Supplementary Table 5: Table summarizing principal patient features and their cluster attribution. More extensive information can be seen at http://www.ebi.ac.uk/arrayexpress; accession: E-MTAB-1781. Supplementary Table 6: Table summarizing the mitoscore and its components for each gene of the mitochondrial signature; genes are order based on decreasing mitoscore. Supplementary Table 7: List of the top 200 differentially expressed genes between Cluster 1 (left) and Cluster 2 (right) Supplementary Table 8: List of Cluster 1 and Cluster 2 associated genes used for the pathway network analysis. Supplementary Table 9: List of the ClueGo pathways obtained from the pathway network analysis.
- Open Access
- 1 December 2021
- Published by Elsevier in Sensors and Actuators B: Chemical
- Vol. 348
Nanomechanical bio-sensing for fast and reliable detection of viability and susceptibility of microorganisms
- 1 December 2021
- Published by Elsevier in Sensors and Actuators B: Chemical
- Vol. 348
Open AccessNanomechanical bio-sensing for fast and reliable detection of viability and susceptibility of microorganisms
- 22 December 2020
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 15 (1) , 944-953
Environmental Control of Amyloid Polymorphism by Modulation of Hydrodynamic Stress
The phenomenon of amyloid polymorphism is a key feature of protein aggregation. Unravelling this phenomenon is of great significance for understanding the underlying molecular mechanisms associated with neurodegenerative diseases and for the development of amyloid-based functional biomaterials. However, the understanding of the molecular origins and the physicochemical factors modulating amyloid polymorphs remains challenging. Herein, we demonstrate an association between amyloid polymorphism and environmental stress in solution, induced by an air/water interface in motion. Our results reveal that low-stress environments produce heterogeneous amyloid polymorphs, including twisted, helical, and rod-like fibrils, whereas high-stress conditions generate only homogeneous rod-like fibrils. Moreover, high environmental stress converts twisted fibrils into rod-like fibrils both in-pathway and after the completion of mature amyloid formation. These results enrich our understanding of the environmental origin of polymorphism of pathological amyloids and shed light on the potential of environmentally controlled fabrication of homogeneous amyloid biomaterials for biotechnological applications.
- 22 December 2020
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 15 (1) , 944-953
Environmental Control of Amyloid Polymorphism by Modulation of Hydrodynamic Stress
The phenomenon of amyloid polymorphism is a key feature of protein aggregation. Unravelling this phenomenon is of great significance for understanding the underlying molecular mechanisms associated with neurodegenerative diseases and for the development of amyloid-based functional biomaterials. However, the understanding of the molecular origins and the physicochemical factors modulating amyloid polymorphs remains challenging. Herein, we demonstrate an association between amyloid polymorphism and environmental stress in solution, induced by an air/water interface in motion. Our results reveal that low-stress environments produce heterogeneous amyloid polymorphs, including twisted, helical, and rod-like fibrils, whereas high-stress conditions generate only homogeneous rod-like fibrils. Moreover, high environmental stress converts twisted fibrils into rod-like fibrils both in-pathway and after the completion of mature amyloid formation. These results enrich our understanding of the environmental origin of polymorphism of pathological amyloids and shed light on the potential of environmentally controlled fabrication of homogeneous amyloid biomaterials for biotechnological applications.
- 4 June 2020
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 12 (29) , 33163-33172
Fiber-Tip Polymer Microcantilever for Fast and Highly Sensitive Hydrogen Measurement
Hydrogen as an antioxidant gas has been widely used in medical and biological fields for preventing cancer or for treating inflammation. However, controlling the hydrogen concentration is crucial for the practical use due to its explosive property when its volume concentration in air reaches the explosive limit (4%). In this work, a polymer based microcantilever (μ-cantilever) hydrogen sensor located at the end of a fiber tip is proposed to detect hydrogen concentration in medical and biological applications. The proposed sensor was developed using femtosecond (FS) laser-induced two-photon polymerization (TPP) to print the polymer μ-cantilever, and magnetron sputtering to coat a palladium (Pd) film on the upper surface of the μ-cantilever. Such a device exhibits a high sensitivity, roughly 2 nm %-1 when the hydrogen concentration rises from 0% to 4.5%(v/v) and a short response time, around 13.5 s at 4%(v/v), making it suitable for medical and environmental application. In addition to providing an ultra-compact optical solution for fast and highly sensitive hydrogen measurement, the polymer μ-cantilever fiber sensor can be used for diverse medical and biological sensing applications by replacing Pd with other functional materials.
- 4 June 2020
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 12 (29) , 33163-33172
Fiber-Tip Polymer Microcantilever for Fast and Highly Sensitive Hydrogen Measurement
Hydrogen as an antioxidant gas has been widely used in medical and biological fields for preventing cancer or for treating inflammation. However, controlling the hydrogen concentration is crucial for the practical use due to its explosive property when its volume concentration in air reaches the explosive limit (4%). In this work, a polymer based microcantilever (μ-cantilever) hydrogen sensor located at the end of a fiber tip is proposed to detect hydrogen concentration in medical and biological applications. The proposed sensor was developed using femtosecond (FS) laser-induced two-photon polymerization (TPP) to print the polymer μ-cantilever, and magnetron sputtering to coat a palladium (Pd) film on the upper surface of the μ-cantilever. Such a device exhibits a high sensitivity, roughly 2 nm %-1 when the hydrogen concentration rises from 0% to 4.5%(v/v) and a short response time, around 13.5 s at 4%(v/v), making it suitable for medical and environmental application. In addition to providing an ultra-compact optical solution for fast and highly sensitive hydrogen measurement, the polymer μ-cantilever fiber sensor can be used for diverse medical and biological sensing applications by replacing Pd with other functional materials.
- Open Access
- 16 April 2020
- Published by Peertechz Publications Private Limited in Journal of Clinical Microbiology and Biochemical Technology
- Vol. 6 (1) , 010-013
Towards a fast detection of microbial resistance to antibiotics
The antimicrobial resistance is the ability of bacteria and fungi to proliferate even in presence of antibiotic or antimycotic drugs [1].
- 16 April 2020
- Published by Peertechz Publications Private Limited in Journal of Clinical Microbiology and Biochemical Technology
- Vol. 6 (1) , 010-013
Open AccessTowards a fast detection of microbial resistance to antibiotics
The antimicrobial resistance is the ability of bacteria and fungi to proliferate even in presence of antibiotic or antimycotic drugs [1].